Skip to content
10-K

Annual Report

BICARA THERAPEUTICS INC. BCAX

0001628280-26-022010

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 24, 2026 65.47M sh
Shares Diluted FY 2025 · Dec 31, 2025 54.68B sh
Shares Diluted FY 2025 · Dec 31, 2024 16.81B sh
Capex FY 2025 · Dec 31, 2025 $280K
Capex FY 2025 · Dec 31, 2024 $71K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$106.83M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$74.75M
Short Term Investments FY 2025 · Dec 31, 2025 $318.12M
Short Term Investments FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $96.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $489.71M
Stockholders Equity FY 2025 · Dec 31, 2025 $401.45M
Stockholders Equity FY 2025 · Dec 31, 2024 $491.88M
Stockholders Equity FY 2025 · Dec 31, 2023 −$148.77M
Current Liabilities FY 2025 · Dec 31, 2025 $28.95M
Current Liabilities FY 2025 · Dec 31, 2024 $17.99M
Total Liabilities FY 2025 · Dec 31, 2025 $29.54M
Total Liabilities FY 2025 · Dec 31, 2024 $18.12M
Current Assets FY 2025 · Dec 31, 2025 $422.05M
Current Assets FY 2025 · Dec 31, 2024 $502.53M
Total Assets FY 2025 · Dec 31, 2025 $430.99M
Total Assets FY 2025 · Dec 31, 2024 $510M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.52
Eps Diluted FY 2025 · Dec 31, 2024 −$4.05
Eps Basic FY 2025 · Dec 31, 2025 −$2.52
Eps Basic FY 2025 · Dec 31, 2024 −$4.05
Sga Expense FY 2025 · Dec 31, 2025 $30.51M
Sga Expense FY 2025 · Dec 31, 2024 $18.77M
Net Income FY 2025 · Dec 31, 2025 −$137.95M
Net Income FY 2025 · Dec 31, 2024 −$68M
Operating Income FY 2025 · Dec 31, 2025 −$155.6M
Operating Income FY 2025 · Dec 31, 2024 −$82.39M